{
  "image_filename": "figure_p4_det_3_007.png",
  "image_path": "FlublokPI/extracted/figures/figure_p4_det_3_007.png",
  "image_type": "Figure",
  "page_number": 4,
  "block_id": "det_3_007",
  "claim_id": "claim_006",
  "claim": "Flublok is produced using a novel production platform in which recombinant HA is expressed in insect cells using a baculovirus expression vector system (BEVS).",
  "supports_claim": false,
  "explanation": "A table displaying attack rates (n/N and %), sample sizes (n), relative risks (RR), and relative vaccine efficacy percentages (95% CI) for RT-PCR\u2013confirmed influenza cases, comparing Flublok with a comparator vaccine (Fluarix Quadrivalent). does not support the claim because the image only presents clinical efficacy data (attack rates, RR, VE) and contains no information on manufacturing methods or the use of a baculovirus expression vector system in insect cells.",
  "model_used": "o4-mini",
  "detailed_analysis": {
    "supports_claim": false,
    "image_description": "A table displaying attack rates (n/N and %), sample sizes (n), relative risks (RR), and relative vaccine efficacy percentages (95% CI) for RT-PCR\u2013confirmed influenza cases, comparing Flublok with a comparator vaccine (Fluarix Quadrivalent).",
    "evidence_found": null,
    "reasoning": "does not support the claim because the image only presents clinical efficacy data (attack rates, RR, VE) and contains no information on manufacturing methods or the use of a baculovirus expression vector system in insect cells.",
    "confidence_notes": null
  }
}